Literature DB >> 17939167

Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application.

Ting Zhou1, Li Ding, Xiaomin Li, Fei Zhang, Qian Zhang, Bing Gong, Xiaofeng Guo.   

Abstract

A high-performance liquid chromatographic method with UV detection has been developed for the determination of iguratimod (T-614) in rat plasma. Plasma was precipitated with acetonitrile after the addition of the internal standard (IS), N-[4-(2-formylaminoacetyl)-5-methoxy-2-phenoxyphenyl]-methanesulfonamide. The chromatographic separation was achieved on a reversed-phase C(18) column with the mobile phase acetonitrile-acetic acid aqueous solution, pH 4.5 (40:60, v/v), at a flow rate of 1 mL/min, and the UV detection wavelength was set at 257 nm. The calibration curve was linear over the range 0.10-50.0 microg/mL, and the lower limit of quantification was 0.10 microg/mL. The intra- and inter-day relative standard deviations were all less than 11.5%. The method has been successfully applied to study the pharmacokinetics of iguratimod in rats. A single 10 mg/kg dose of iguratimod was given to the rats by intragastric administration. The mean maximum plasma concentration of iguratimod for the six rats was 14.5 microg/mL, and the mean elimination half-life of iguratimod was 4.0 h.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17939167     DOI: 10.1002/bmc.921

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  3 in total

1.  Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.

Authors:  K Morimoto; A Miura; Keiichi Tanaka
Journal:  Inflamm Res       Date:  2017-06-13       Impact factor: 4.575

2.  A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.

Authors:  Feng Xiao; Feng Zhang; Ling-Ling Zhang; Wei Wei
Journal:  Eur J Clin Pharmacol       Date:  2017-10-19       Impact factor: 2.953

3.  In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics.

Authors:  Zhenzhen Ma; Cheng Tao; Lin Sun; Shengbei Qi; Yuan Le; Jiexin Wang; Changhong Li; Xiangyuan Liu; Jianjun Zhang; Jinxia Zhao
Journal:  Int J Nanomedicine       Date:  2019-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.